58th ASH Annual Meeting & Exposition
The premier event in malignant & non-malignant hematology
December 3-6, 2016, San Diego, CA
LINKS TO WEBCASTS AT THE BOTTOM OF PAGE
Read ASH News Daily 2016:
Simultaneous Oral Sessions (links to program & abstracts)
ASH Press Release: Highly Anticipated Late-Breaking Abstracts Session to Feature Groundbreaking Scientific Data During 58th ASH Annual Meeting
(SAN DIEGO, December 6, 2016) — The American Society of Hematology (ASH), the world’s largest professional society concerned with the causes and treatment of blood disorders, will highlight the following novel studies in its late-breaking abstracts session today at the 58th ASH Annual Meeting and Exposition in San Diego:
• Additions to Standard Multiple Myeloma Therapy Do Not Appear to Yield Additional Benefit
• IKZF1 Gene Mutations Found to Increase Hereditary Risk for Acute Lymphocytic Leukemia in Children
• Cancer Drug Ibrutinib Found Helpful in Treating Graft Versus Host Disease After Stem Cell Transplant
• New Data Shed Light on Potential Advantages of Pacritinib for Patients with Myelofibrosis
• First Multicenter Trial Finds CAR T-Cell Immunotherapy Effective, Feasible for Hard-to-Treat Lymphoma